Implantica AG (STU:8IM1) ROE %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8IM1 Implantica AG STU:8IM1
36 GF Score
Price €5.60
View Full Analysis

What is Implantica AG ROE %?

Implantica AG STU:8IM1 +1.82% 36 ROE % is 0.00% as of . 20. GuruFocus rates STU:8IM1 with a GF Score™ of 36/100. Among 799 Medical Devices & Instruments companies, Implantica AG ranks worse than 125156.32% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Implantica AG's annualized net income for the quarter that ended in . 20 was € Mil. Implantica AG's average Total Stockholders Equity over the quarter that ended in . 20 was € Mil. Therefore, Implantica AG's annualized ROE % for the quarter that ended in . 20 was %.

The historical rank and industry rank for Implantica AG's ROE % or its related term are showing as below:

STU:8IM1's ROE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.42
* Ranked among companies with meaningful ROE % only.

Implantica AG  (STU:8IM1) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*( / )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= ( / ) * ( / ) * ( / ) * ( / ) * ( / )
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= * * % * *
= %

Note: The net income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Implantica AG ROE % Related Terms


Implantica AG ROE % Historical Data

* Premium members only.

The historical data trend for Implantica AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Implantica AG ROE % Chart

Implantica AG Annual Data
Trend
ROE %

Implantica AG Semi-Annual Data
ROE %

STU:8IM1 vs : ROE % Comparison

For the Medical Devices subindustry, Implantica AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Implantica AG ROE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Implantica AG's ROE % distribution charts can be found below:

* The bar in red indicates where Implantica AG's ROE % falls into.


STU:8IM1
36GF Score
Implantica AG STU:8IM1
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Implantica AG ROE % Calculation

Implantica AG's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

Implantica AG's annualized ROE % for the quarter that ended in . 20 is calculated as

ROE %=Net Income (Q: . 20 )/( (Total Stockholders Equity (Q: . 20 )+Total Stockholders Equity (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Implantica AG (STU:8IM1) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Implantica AG and its competitors. According to the industry distribution chart, Implantica AG ranks #999999 out of 799 companies in the Medical Devices & Instruments industry.
Is Implantica AG's ROE % too high?
Implantica AG's current ROE % is 0.00%. Based on the distribution chart, Implantica AG ranks #999999 out of 799 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Implantica AG has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Implantica AG's ROE % compare to ?
According to the Medical Devices & Instruments industry distribution chart, Implantica AG ranks #999999 out of 799 companies for ROE %. This places Implantica AG in the lower half of its industry. The industry median ROE % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Implantica AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Implantica AG's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Implantica AG stock overvalued right now?
Implantica AG (STU:8IM1) has a current ROE % of 0.00%. The current ROE % is 0.00%. Implantica AG's overall GF Score™ is 36/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Implantica AG (STU:8IM1), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Implantica AG Business Description

Comparable Companies
Other Exchanges IMP A SDB:Sweden
Address Aeulestrasse 15, Vaduz, LIE, 9490
Implantica AG is a medtech group providing effective care for serious health conditions and improving patients' quality of life by bringing technology into the body. The therapies Implantica develops are based on implants that are medical devices inserted into the patient's body and are intended to remain in place permanently or semi-permanently, using electrical power provided by a battery. The company has developed a broad, patent-protected product pipeline based partly on its two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body, and communicate with the caregiver at a distance, and a wireless energising platform designed to power remote-controlled implants wirelessly through intact skin.
36GF Score

Get the complete analysis for STU:8IM1

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.60
Price